Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 2/20 | 0.57 |
| ▸ | FGF1 | P05230 | 1/20 | 0.57 |
| ▸ | FGF2 | P09038 | 1/20 | 0.57 |
| ▸ | VEGFA | P15692 | 1/20 | 0.57 |
| ▸ | MDK | P21741 | 4/20 | 0.57 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | GIGYF2 | Q6Y7W6 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705327 | 0.96 | MDK (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067561 | 0.96 | MDK (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067560 | 0.96 | MDK (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL23126167 | 0.96 | MDK (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL23126027 | 0.92 | FGF1 (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL23126139 | 0.92 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL20519908 | 0.92 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067580 | 0.92 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067582 | 0.92 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067597 | 0.92 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | HPSE 762/4885FGF1 4232/4885FGF2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.